

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ALLIA.143CP3APPLICATION NO.
09/873,901INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Habib ZaghouaniFILING DATE
June 4, 2001GROUP
1644RECEIVED
FEB 11 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,969,109	10/19/99	Bona, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PN	2	WO 98/19584	06/27/98	PCT				
PN	3	WO 99/09064	02/25/99	PCT				
PN	4	WO 00/01732	01/13/00	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PN	5 ✓	Adorini, et al., New Perspectives on Immunointervention in Autoimmune Diseases, Immunol. Today, 11(11):383-386 (1990).
	6 ✓	Cullen, et al., A Divalent Major Histocompatibility Complex/IgG1 Fusion Protein Induces Antigen-specific T Cell Activation <i>in vitro</i> and <i>in vivo</i> , Cellular Immunology 192(1):54-62 (1999).
	7 ✓	Endoh, et al., Studies of Experimental Allergic Encephalomyelitis in Old Mice, J. of Neuroimmunol., 29:21-31 (1990).
	8 ✓	Gosselin, et al., Enhanced Antigen Presentation Using Human Fcγ Receptor (Monocyte/Macrophage)-Specific Immunogens, J. Immunol., 149(11):3477-3481 (1992).
	9 ✓	Muller, et al., Selective <i>in vivo</i> Inhibition of T Cell Activation by Class II MHC-Binding Peptides Administered in Soluble Form, J. Immunol., 145(12):4006-4011 (1990).
	10 ✓	Riechmann, et al., Reshaping human antibodies for therapy, Nature, Vol. 332, March 24: 323-327 (1988).
	11 ✓	Sollazzo, et al., Expression of an exogenous peptide epitope genetically engineered in the variable domain of an immunoglobulin: implications for antibody and peptide folding, Protein Engineering, Vol. 4, No. 2: 215-220 (1990).
	12 ✓	Takemori, et al., Mechanism of Neonatally Induced Idiotype Suppression and its Relevance for the Acquisition of Self-tolerance, Immunological Reviews, 79:103-117.
	13 ✓	Zaghouani, et al., Engineered Immunoglobulin Molecules as Vehicles for T Cell Epitopes, Intern. Rev. Immunol., 10: 265-278 (1993).
	14 ✓	Zaghouani, Habib, U.S. App. No. 10/000,868, filed 11/30/01, entitled "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143DV1.
PN	15	International Search Report for co-pending Application No. PCT/US01/40834.

S:\DOCS\SGJ\SGJ-1415.DOC:dmb
012202

EXAMINER	<i>PN</i>	DATE CONSIDERED	6/28/04
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			